Log in

NASDAQ:CLSDClearside Biomedical Stock Price, Forecast & News

$1.76
-0.03 (-1.68 %)
(As of 08/7/2020 04:00 PM ET)
Add
Compare
Today's Range
$1.71
Now: $1.76
$1.79
50-Day Range
$1.64
MA: $1.86
$2.06
52-Week Range
$0.56
Now: $1.76
$4.13
Volume125,242 shs
Average Volume661,265 shs
Market Capitalization$78.97 million
P/E RatioN/A
Dividend YieldN/A
Beta0.96
Clearside Biomedical, Inc., a late-stage clinical biopharmaceutical company, develops pharmacological therapies to restore and preserve vision for people with serious eye diseases. It develops XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of macular edema associated with uveitis, diabetic macular edema, and macular edema associated with retinal vein occlusion. The company was founded in 2011 and is headquartered in Alpharetta, Georgia.
Read More
Clearside Biomedical logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.3Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.32 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:CLSD
CUSIPN/A
Phone678-270-3631

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$2.17 million
Book Value$0.25 per share

Profitability

Net Income$-30,770,000.00
Net Margins-293.61%

Miscellaneous

Employees50
Market Cap$78.97 million
Next Earnings Date8/10/2020 (Confirmed)
OptionableOptionable
$1.76
-0.03 (-1.68 %)
(As of 08/7/2020 04:00 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive CLSD News and Ratings via Email

Sign-up to receive the latest news and ratings for CLSD and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Clearside Biomedical (NASDAQ:CLSD) Frequently Asked Questions

How has Clearside Biomedical's stock been impacted by COVID-19 (Coronavirus)?

Clearside Biomedical's stock was trading at $2.59 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, CLSD stock has decreased by 32.0% and is now trading at $1.76.
View which stocks have been most impacted by Coronavirus
.

Do Wall Street analysts recommend investors buy shares of Clearside Biomedical?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Clearside Biomedical in the last year. There are currently 3 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Clearside Biomedical
.

When is Clearside Biomedical's next earnings date?

Clearside Biomedical is scheduled to release its next quarterly earnings announcement on Monday, August 10th 2020.
View our earnings forecast for Clearside Biomedical
.

How can I listen to Clearside Biomedical's earnings call?

Clearside Biomedical will be holding an earnings conference call on Monday, August 10th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

How were Clearside Biomedical's earnings last quarter?

Clearside Biomedical Inc (NASDAQ:CLSD) issued its quarterly earnings results on Friday, May, 8th. The company reported ($0.07) EPS for the quarter, topping the Zacks' consensus estimate of ($0.11) by $0.04. The business had revenue of $4.10 million for the quarter, compared to analyst estimates of $4 million. Clearside Biomedical had a negative net margin of 293.61% and a negative return on equity of 165.19%.
View Clearside Biomedical's earnings history
.

What price target have analysts set for CLSD?

6 equities research analysts have issued 12 month target prices for Clearside Biomedical's shares. Their forecasts range from $4.00 to $8.00. On average, they expect Clearside Biomedical's share price to reach $5.75 in the next year. This suggests a possible upside of 226.7% from the stock's current price.
View analysts' price targets for Clearside Biomedical
.

Has Clearside Biomedical been receiving favorable news coverage?

Headlines about CLSD stock have been trending very positive this week, according to InfoTrie. InfoTrie identifies negative and positive press coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Clearside Biomedical earned a media sentiment score of 4.0 on InfoTrie's scale. They also gave media stories about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the stock's share price in the next few days.
View the latest news about Clearside Biomedical
.

Are investors shorting Clearside Biomedical?

Clearside Biomedical saw a increase in short interest in July. As of July 31st, there was short interest totaling 1,660,000 shares, an increase of 5.7% from the July 15th total of 1,570,000 shares. Based on an average daily volume of 395,900 shares, the short-interest ratio is presently 4.2 days. Currently, 5.0% of the company's stock are sold short.
View Clearside Biomedical's Current Options Chain
.

Who are some of Clearside Biomedical's key competitors?

What other stocks do shareholders of Clearside Biomedical own?

Who are Clearside Biomedical's key executives?

Clearside Biomedical's management team includes the following people:
  • Dr. George M. Lasezkay Pharma.D., J.D., Interim CEO & Director (Age 67)
  • Mr. Charles A. Deignan, Chief Financial Officer (Age 55)
  • Mr. Stephen C. Kilmer, Investor Relations Officer (Age 53)
  • Mr. Leslie B. Zacks, Gen. Counsel, Chief Compliance Officer & Sec. (Age 50)
  • Mr. Rick McElheny, VP of Corp. Devel.

When did Clearside Biomedical IPO?

(CLSD) raised $50 million in an initial public offering on Thursday, June 2nd 2016. The company issued 7,200,000 shares at a price of $7.00 per share. Cowen and Company and Stifel served as the underwriters for the IPO and Needham & Company, Wedbush PacGrow was co-manager.

What is Clearside Biomedical's stock symbol?

Clearside Biomedical trades on the NASDAQ under the ticker symbol "CLSD."

Who are Clearside Biomedical's major shareholders?

Clearside Biomedical's stock is owned by many different institutional and retail investors. Top institutional shareholders include Principal Financial Group Inc. (0.08%), First Citizens Bank & Trust Co. (0.03%) and Virtu Financial LLC (0.03%). Company insiders that own Clearside Biomedical stock include Charles A Deignan, Clay Thorp, George M Lasezkay and Nancy J Hutson.
View institutional ownership trends for Clearside Biomedical
.

Which institutional investors are buying Clearside Biomedical stock?

CLSD stock was purchased by a variety of institutional investors in the last quarter, including Principal Financial Group Inc., First Citizens Bank & Trust Co., and Virtu Financial LLC. Company insiders that have bought Clearside Biomedical stock in the last two years include Charles A Deignan, Clay Thorp, George M Lasezkay, and Nancy J Hutson.
View insider buying and selling activity for Clearside Biomedical
.

How do I buy shares of Clearside Biomedical?

Shares of CLSD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Clearside Biomedical's stock price today?

One share of CLSD stock can currently be purchased for approximately $1.76.

How big of a company is Clearside Biomedical?

Clearside Biomedical has a market capitalization of $78.97 million and generates $2.17 million in revenue each year. The company earns $-30,770,000.00 in net income (profit) each year or ($0.81) on an earnings per share basis. Clearside Biomedical employs 50 workers across the globe.

What is Clearside Biomedical's official website?

The official website for Clearside Biomedical is www.clearsidebio.com.

How can I contact Clearside Biomedical?

Clearside Biomedical's mailing address is 900 NORTH POINT PARKWAY SUITE 200, ALPHARETTA GA, 30005. The company can be reached via phone at 678-270-3631 or via email at [email protected]

This page was last updated on 8/8/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.